Relay Therapeutics (RLAY)
(Delayed Data from NSDQ)
$3.65 USD
+0.29 (8.63%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $3.64 -0.01 (-0.27%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Fundamental Charts
About Dividend Yield (TTM)
Relay Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Drugs industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
RLAY 3.65 +0.29(8.63%)
Will RLAY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RLAY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RLAY
RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?
Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?
RLAY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith?
Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process?
Other News for RLAY
Relay Therapeutics: What's Next For H2 2025?
Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights ...
Relay Therapeutics has positive read from Celcuity data, says Barclays
Claire Mazumdar Joins Relay Therapeutics as Director
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors | RLAY Stock News